Cleveland BioLabs Wins Grant for Research in Mitigation of Radiation Damage
Cleveland BioLabs, a drug discovery and development company, has received a $774,183 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic damage from radiation exposure.
The grant program, medical countermeasures to enhance platelet regeneration and increase survival following radiation exposure, is funded through the Project BioShield Act of 2004 and administered by the Department of Health and Human Services.
The goal of this program is to accelerate the development of safe and effective medical products to mitigate and treat thrombocytopenia and to enhance platelet regeneration after radiation exposure from radiological and nuclear terrorist attacks. Specifically, this initiative supports R&D of promising new approaches and medical products to enhance platelet regeneration and yield improved survival.
Cleveland BioLabs has recently received an allowance from the FDA to begin Phase I clinical trials in human volunteers with Protectan CBLB502. Protectan CBLB502 is being developed under the FDA’s animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident.
Andrei Gudkov, Cleveland BioLabs’s chief scientific officer, said: “This grant in particular focuses on the remarkable ability of Protectan CBLB502 to mitigate the occurrence and severity of thrombocytopenia, as well as accelerate recovery time in non-human primate models. We will be further examining this aspect of Protectan CBLB502′s activity and working towards optimizing potential regimens of administration for enhanced mitigation of radiation-induced thrombocytopenia and mortality.
“Protectan CBLB502′s multiple mechanisms of action set it apart from other potential radiation protectors or mitigators, in part due to its activity in both hematopoietic and gastrointestinal aspects of acute radiation syndrome. Protectan CBLB502 may represent a valuable potential addition to the strategic national stockpile.”